ADCT Adc Therapeutics SA

  1. Stocks
  2. Healthcare
  3. NYSE: ADCT

Price (delayed)

$1.19

Market cap

$151.36M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.99

Enterprise value

$37.02M

?
Relative Growth: Rel. Growth: 24
Relative Strength: Rel. Strength: 1
Relative Valuation: Rel. Valuation: 20
Relative Profitability: Rel. Profitability: 26

adc therapeutics is a biotechnology company located in lausanne, vaud, switzerland.

Highlights
Adc Therapeutics's EPS has increased by 31% YoY and by 12% QoQ
The company's net income rose by 9% YoY and by 4% QoQ
Adc Therapeutics's equity has decreased by 16% from the previous quarter but it has increased by 9% YoY
The gross profit has contracted by 4.9% from the previous quarter but it has grown by 2.1% YoY
Adc Therapeutics's quick ratio has decreased by 7% from the previous quarter
Adc Therapeutics's gross margin has decreased by 2.4% from the previous quarter and by 2.2% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://adctherapeutics.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of ADCT

ADCT stock price

How has the Adc Therapeutics stock price performed over time
Intraday
4.39%
1 week
14.42%
1 month
-62.46%
1 year
-57.5%
YTD
-66.29%
QTD
11.21%

Financial performance

How have Adc Therapeutics's revenue and profit performed over time
Revenue
$79.18M
Gross profit
$71.82M
Operating income
-$118.28M
Net income
-$136.99M
Gross margin
90.7%
Net margin
-173%
Adc Therapeutics's net margin has increased by 12% YoY
ADCT's operating margin is up by 10% year-on-year
The company's net income rose by 9% YoY and by 4% QoQ
Adc Therapeutics's operating income has increased by 6% YoY and by 2.6% QoQ

Price vs fundamentals

How does ADCT's price correlate with its fundamentals

Growth

What is Adc Therapeutics's growth rate over time

Valuation

What is Adc Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
2.32
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.47
Adc Therapeutics's EPS has increased by 31% YoY and by 12% QoQ
Adc Therapeutics's equity has decreased by 16% from the previous quarter but it has increased by 9% YoY
ADCT's price to sales (P/S) is 82% lower than its 5-year quarterly average of 12.7 and 61% lower than its last 4 quarters average of 6.0
The revenue has increased by 4.4% YoY but it has decreased by 2.7% from the previous quarter

Efficiency

How efficient is Adc Therapeutics business performance
Adc Therapeutics's return on sales has increased by 19% YoY and by 3.6% QoQ
The ROA has grown by 5% from the previous quarter

Dividends

What is ADCT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ADCT.

Financial health

How did Adc Therapeutics financials performed over time
Adc Therapeutics's total assets is 43% less than its total liabilities
Adc Therapeutics's total assets has decreased by 10% from the previous quarter but it has increased by 7% YoY
ADCT's current ratio is down by 8% year-on-year and by 6% since the previous quarter
Adc Therapeutics's debt is 154% higher than its equity
Adc Therapeutics's equity has decreased by 16% from the previous quarter but it has increased by 9% YoY
The debt to equity has grown by 14% from the previous quarter but it has contracted by 6% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.